-
Mashup Score: 1
Listen to ASCO’s Journal of Clinical Oncology essay, “The Heritability of Cancer” by Dr. Leeat Granek, Associate Professor at York University in Toronto, Canada. The essay is followed by an interview with Granek and host Dr. Lidia Schapira. Granek shares how her mother’s diagnose with breast cancer continues to shape her own life and experiences.
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 49
PURPOSE Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4–blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with BRAFV600-mutant metastatic melanoma, leading to broad regulatory approval. Little prospective data exist to guide the choice of either initial therapy or treatment sequence in this population. This study was conducted to determine which initial treatment or treatment sequence produced the best efficacy. PATIENTS AND METHODS In a phase III trial, patients with treatment-naive BRAFV600-mutant metastatic melanoma were randomly assigned to receive either combination nivolumab/ipilimumab (arm A) or dabrafenib/trametinib (arm B) in step 1, and at disease progression were enrolled in step 2 to receive the alternate therapy, dabrafenib/trametinib (arm C) or nivolumab/ipilimumab (arm D). The primary end point was 2-year overall survival (OS). Secondary end points were 3-year OS, objective response rate, response dur
Source: ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet-
📢 Read the 2023 #JCO Paper of the Year! "Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134" ➡️ https://t.co/iRDd5VX26H @eaonc https://t.co/qogV3c7F9E
-
-
Mashup Score: 0
PURPOSE CNS progression or relapse is an uncommon but devastating complication of aggressive B-cell lymphoma. There is no consensus regarding the optimal approach to CNS prophylaxis. This study was designed to determine whether high-dose methotrexate (HD-MTX) is effective at preventing CNS progression in patients at high risk of this complication. PATIENTS AND METHODS Patients age 18-80 years with aggressive B-cell lymphoma and high risk of CNS progression, treated with curative-intent anti–CD20-based chemoimmunotherapy, were included in this international, retrospective, observational study. Cause-specific hazard ratios (HRs) and cumulative risks of CNS progression were calculated according to use of HD-MTX, with time to CNS progression calculated from diagnosis for all patients (all-pts) and from completion of frontline systemic lymphoma induction therapy, for patients in complete response at completion of chemoimmunotherapy (CR-pts). RESULTS Two thousand four hundred eighteen all-pt
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
✅ Check out what’s popular this week in #JCO: High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell #Lymphoma ➡️ https://t.co/cufyFMRDRp #Lymsm @Dr_KatLewis @chanyooncheah https://t.co/bLN7kzjmCe
-
-
Mashup Score: 0
In the companion to this article, Peters et al 1 reported that the addition of concomitant chemotherapy to adjuvant radiation therapy in the treatment of women with high-risk factors after radical hysterectomy for cervical cancer significantly improved both progression-free survival and overall survival. This became the standard of care and remains so today. AUTHOR’S DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by the author of this manuscript.
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎉 Celebrating #JCO's 40th: Read the Flashback Foreword by Dr. Fleming to the top-cited #JCO article, Concurrent CT/RT for Cervical Cancer (2000) 👇 https://t.co/XAwexoARLj https://t.co/1qzVUAcqHd
-
-
Mashup Score: 2
Part 2 of the COLUMBUS trial, reported in the article 10 that accompanies this editorial, confirmed that the combination of binimetinib to encorafenib 300 mg once daily, which is lower than the maximum tolerated combination dose (450 mg once daily), is associated with improved outcomes compared with single-agent encorafenib (dosed at 300 mg once daily) in patients with previously untreated, advanced BRAF -mutant melanoma. However, past and emerging data support the use of frontline immunotherapy instead
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 #JCO #Editorial: To inhibit or not to inhibit MEK with BRAF inhibitors: Is that the question? https://t.co/JM4BW8mY7c #Melanoma #melsm
-
-
Mashup Score: 0Chemoimmunotherapy for Untreated Lung Cancer Brain Metastases: Systemic Before Local Therapy? - 6 month(s) ago
In the article that accompanies this editorial, Nadal et al 8 present the results of a single-arm, multicenter phase II study (Atezo-Brain) investigating the safety and efficacy of atezolizumab in combination with carboplatin and pemetrexed in patients with advanced, nonsquamous non–small-cell lung cancer with clinically stable, untreated brain metastases. In addition to demonstrating the intracranial safety and efficacy of chemoimmunotherapy, even in patients with a considerable burden of intracranial
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 #JCO #Editorial: Chemoimmunotherapy for untreated #LungCancer brain metastases: Systemic before local therapy? https://t.co/mhHTzqzRQq #LCSM #ImmunoOnc @Benjamin_Y_Lu @NadalErnest
-
-
Mashup Score: 3
In the companion to this article, Peters et al 1 reported that the addition of concomitant chemotherapy to adjuvant radiation therapy in the treatment of women with high-risk factors after radical hysterectomy for cervical cancer significantly improved both progression-free survival and overall survival. This became the standard of care and remains so today. AUTHOR’S DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by the author of this manuscript.
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎉 Celebrating #JCO's 40th: Read the Flashback Foreword by Dr. Fleming of the top-cited #JCO article, Concurrent CT/RT for Cervical Cancer (2000) 👉 https://t.co/o3e2qKjsl8 https://t.co/T2IHpVFi1C
-
-
Mashup Score: 2
In a multicenter RCT (n = 78), radiation to high-risk asymptomatic bone metastases ⬇ skeletal-related events and prolonged OS.
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
👋 Check out what’s popular in #JCO: Prophylactic Radiation Therapy Versus Standard of Care for Patients With High-Risk Asymptomatic Bone Metastases: A Multicenter, Randomized Phase II Clinical Trial 👉 https://t.co/VYbtzq3SXP @ErinGillespieMD #radonc https://t.co/BwMcWcauiA
-
-
Mashup Score: 1De Novo Oligometastatic Breast Cancer - 7 month(s) ago
De novo oligometastatic breast cancer, a unique disease needing new treatment paradigms.
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🤔 #JCO #CommentsAndControversies: De novo oligometastatic #BreastCancer, a unique disease needing new treatment paradigms: https://t.co/ZRnygP1duh #BCSM @YaleCancer @YaleBreast
-
-
Mashup Score: 1Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs - 7 month(s) ago
In 2012, two of us wrote in these pages a critique arguing against the use of progression-free survival (PFS) as a primary end point in randomized controlled trials (RCTs) evaluating anticancer drugs. 1 Drugs should be approved if there is evidence that they benefit patients in comparison with best standard care. Regardless of medical disease, one can o nly benefit patients by improving their duration or quality of survival. Despite evidence summarized below that PFS is rarely a surrogate for overall
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
👀 Check out what’s popular this week in #JCO: Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs ➡️ https://t.co/XUf97FwYt2 @EAEisenhauer @oncology_bg https://t.co/P0A4Rec2R0
-
Listen to #JCO Art of Oncology essay, “The Heritability of Cancer” by Dr. Leeat Granek. Granek shares how her mother's diagnose with breast cancer continues to shape her own life and experiences. ➡️ https://t.co/ZUYOQtMPJb https://t.co/AtcIDD2THq